(firstQuint)Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study.

 This is a prospective, multi-center, IDE clinical study designed to evaluate the safety of the Model 1457Q Quartet LV lead.

 A minimum of 94 and a maximum of 430 subjects will be enrolled in this study at up to 40 centers worldwide.

 All subjects successfully implanted with a Quartet 1457Q lead will be followed every 6 months post implant until Pre Market Approval (PMA) is obtained or the study is closed.

.

 Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study@highlight

The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.

